- Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
- Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
- Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
- Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
- Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
- Purple Biotech Reaches Recommended Phase 2 Dose for NT219
- Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
- Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
- Purple Biotech Fortifies NT219 Patent Protection
More ▼
Key statistics
On Thursday, Purple Biotech Ltd (PPBT:TLV) closed at 28.10, 64.33% above the 52 week low of 17.10 set on May 16, 2024.
52-week range
Open | 26.80 |
---|---|
High | 28.10 |
Low | 25.50 |
Bid | 27.90 |
Offer | 28.10 |
Previous close | 26.40 |
Average volume | 426.97k |
---|---|
Shares outstanding | 274.95m |
Free float | 273.89m |
P/E (TTM) | -- |
Market cap | 76.18m ILS |
EPS (TTM) | -0.2744 ILS |
Data delayed at least 20 minutes, as of May 30 2024 15:24 BST.
More ▼